Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Jinma Xing Zhi Ke Pian
- Development stage
- Phase 3
- Lead developer
- Lanzhou Gufang
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
Jinma Xing Zhi Ke Pian is a Traditional Chinese Medicine (TCM) formulation developed by Chengde Yanfeng Pharmaceutical for the treatment of acute tracheobronchitis. It is specifically indicated for patients presenting with the TCM pattern of phlegm-heat obstructing the lung (痰热阻肺证). The drug is designed to alleviate symptoms such as cough and sputum production by clearing heat and resolving phlegm. It is currently being evaluated in a multicenter, randomized, double-blind, placebo-controlled Phase 3 clinical trial in China to confirm its efficacy and safety in adult populations.
- Other names
- 金麻杏止咳片
Beyond the preview
Go deeper on Jinma Xing Zhi Ke Pian.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Jinma Xing Zhi Ke Pian.